Transarterial Nephrectomy: The Current Status of Experimental and Clinical Studies

Rassweiler, Jens; Prager, P. R.; Haferkamp, Axel; Alken, P.; Kauffmann, G. W.; Richter, G. M.

doi:10.1089/end.2007.9826

Cited by 15 publications

(10 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…With 0.5% drug loading, the viscosity of NMP:PYT at 0.8:0.2 and 0.7:0.3 at 37 C were 115.1 and 47.1 cP, respectively. According to reports 25,26 , Ethibloc Õ , an embolizing product widely used in clinical, has a viscosity of 200 cP. Therefore, we set viscosity no more than 200 cP at 37 C as the prerequisite for easy and safe handling of embolic agent.…”

Section: Selection Of Water-miscible Organic Solventsmentioning

confidence: 99%

Phytantriol based liquid crystal provide sustained release of anticancer drug as a novel embolic agent

Qin

Mei

Shan

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

Phytantriol has received increasing amount of attention in drug delivery system, however, the ability of the phytantriol based liquid crystal as a novel embolic agent to provide a sustained release delivery system is yet to be comprehensively demonstrated. The purpose of this study was to prepare a phytantriol-based cubic phase precursor solution loaded with anticancer drug hydroxycamptothecine (HCPT) and evaluate its embolization properties, in vitro drug release and cytotoxicity. Phase behavior of the phytantriol-solvent-water system was investigated by visual inspection and polarized light microscopy, and no phase transition was observed in the presence of HCPT within the studied dose range. Water uptake by the phytantriol matrices was determined gravimetrically, suggesting that the swelling complied with the second order kinetics. In vitro evaluation of embolic efficacy indicated that the isotropic solution displayed a satisfactory embolization effect. In vitro drug release results showed a sustained-release up to 30 days and the release behavior was affected by the initial composition and drug loading. Moreover, the in vitro cytotoxicity and anticancer activity were evaluated by MTT assay. No appreciable mortality was observed for NIH 3T3 cells after 48 h exposure to blank formulations, and the anticancer activity of HCPT-loaded formulations to HepG2 and SMMC7721 cells was strongly dependent on the drug loading and treatment time. Taken together, these results indicate that phytantriol-based cubic phase embolic gelling solution is a promising potential carrier for HCPT delivery to achieve a sustained drug release by vascular embolization, and this technology may be potential for clinical applications.

show abstract

Section: Selection Of Water-miscible Organic Solventsmentioning

confidence: 99%

Phytantriol based liquid crystal provide sustained release of anticancer drug as a novel embolic agent

Qin

Mei

Shan

et al. 2015

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

show abstract

“…Transarterial nephrectomy seems to be a viable alternative to surgical nephrectomy, although surgical nephrectomy remains as the first-line therapy (1, 2, 4, 5, 6, 7, 8, 9). Therefore, transarterial nephrectomy could be considered especially in patients with a poor condition for surgery or in patients who refuse a surgery.…”

Section: Discussionmentioning

confidence: 99%

“…Renal artery embolization is a minimally invasive procedure which is being increasingly used for the treatment of a wide range of conditions (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13). The indications for renal artery embolization overlap with those for surgical nephrectomy, although the less invasive nature of the former is a major advantage.…”

Section: Introductionmentioning

confidence: 99%

“…Transarterial nephrectomy, i.e., complete renal artery embolization, has the potential to be used as an alternative to surgical nephrectomy with an expectation of complete infarction and non-function of the embolized kidney (2, 3, 4, 5, 6, 7, 8). There have been studies demonstrating transarterial nephrectomy as an alternative to surgery for patients with renal graft intolerance, end-stage kidneys associated with severe hypertension or proteinuria or non-functioning hydronephrotic kidneys (2, 3, 4, 5).…”

Section: Introductionmentioning

confidence: 99%

“…There have been studies demonstrating transarterial nephrectomy as an alternative to surgery for patients with renal graft intolerance, end-stage kidneys associated with severe hypertension or proteinuria or non-functioning hydronephrotic kidneys (2, 3, 4, 5). However, there are only a limited number of reports regarding detailed clinical and/or imaging follow-up data for a variety of clinical indications.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and Efficacy of Transarterial Nephrectomy as an Alternative to Surgical Nephrectomy

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo evaluate the safety and efficacy of transarterial nephrectomy, i.e., complete renal artery embolization, as an alternative to surgical nephrectomy.Materials and MethodsThis retrospective study included 11 patients who underwent transarterial nephrectomy due to a high risk of surgical nephrectomy or their refusal to undergo surgery during the period from April 2002 to February 2013. Medical records and radiographic images were reviewed retrospectively to collect information regarding underlying etiologies, clinical presentations and embolization outcomes.ResultsThe underlying etiologies for transarterial nephrectomy included recurrent hematuria (chronic transplant rejection [n = 3], arteriovenous malformation or fistula [n = 3], angiomyolipoma [n = 1], or end-stage renal disease [n = 1]), inoperable renal or ureteral injury (n = 2), and ectopic kidney with urinary incontinence (n = 1). The technical success rate was 100%, while clinical success was achieved in eight patients (72.7%). Subsequent surgical nephrectomy was required for three patients due to an incomplete nephrectomy effect (n = 2) or necrotic pyelonephritis (n = 1). Procedure-related complications were post-infarction syndrome in one patient and necrotic pyelonephritis in another patient. Of four patients with follow-up CT, four showed renal atrophy and two showed partial renal enhancement. No patient developed a procedure-related hypertension.ConclusionTransarterial nephrectomy may be a safe and effective alternative to surgical nephrectomy in patients with high operative risks.

show abstract

Cytoreductive Nephrectomy

Delacroix¹,

Chapin²,

Karam³

et al. 2015

Kidney Cancer

View full text Add to dashboard Cite

Transarterial Nephrectomy: The Current Status of Experimental and Clinical Studies

Cited by 15 publications

References 55 publications

Phytantriol based liquid crystal provide sustained release of anticancer drug as a novel embolic agent

Phytantriol based liquid crystal provide sustained release of anticancer drug as a novel embolic agent

Safety and Efficacy of Transarterial Nephrectomy as an Alternative to Surgical Nephrectomy

Cytoreductive Nephrectomy

Contact Info

Product

Resources

About